We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amphion Innovations Plc | LSE:AMP | London | Ordinary Share | GB00B0DJNP99 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.15 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMAMP
RNS Number : 7576Z
Amphion Innovations PLC
05 September 2018
Amphion Innovations plc
("Amphion" or "the Company")
Board Change
London and New York: 5 September 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses announces the appointment of Stephen Austin as an additional non-executive director effective immediately. Following a career as a corporate lawyer, qualified executive and corporate stockbroker, Stephen is now the Chief Investment Officer of Plumtree Capital Limited, an FCA authorised corporate finance firm.
Stephen will join the Compensation Committee (as chairman) and the Audit Committee.
Save as disclosed below, there are no further details required to be disclosed pursuant to schedule 2(g) of the AIM rules.
Stephen Michael Austin (age 51) is, or has been in the previous five years, a director or partner, of the following companies:
Current appointments Past appointments EC Aquisitions plc Wisdom Acquisitions plc Plumtree Capital Limited Plumtree Opportunities Limited Plumtree Small Cap Credit LLP
Stephen Austin currently owns 300,000 warrants in the Company. The warrants have an exercise price of 3.5 pence and expire 28 July 2019.
Richard Morgan, CEO, commented: "We have worked with Stephen for four years on a range of projects including the successful AIM IPOs of Motif Bio and Polarean Imaging and now welcome him to the Board."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
For further information please contact:
Amphion Innovations Tel: +1 (212) 210 6224 Charlie Morgan Panmure Gordon Limited (Nominated Adviser Tel: +44 (0)20 7886 and Corporate Broker) 2500 Freddy Crossley / Emma Earl (Corporate Finance) Charlie Leigh-Pemberton (Corporate Broking) Northland Capital Partners Limited (Joint Tel: +44 (0)20 3861 Corporate Broker) 6625 David Hignell (Corporate Finance) Vadim Alexandre (Corporate Broking) Walbrook PR Tel: +44 (0)20 7933 8780 or amphion@walbrookpr.com Anna Dunphy / Paul McManus
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.
On the web: www.amphionplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
BOAFKQDQPBKDACK
(END) Dow Jones Newswires
September 05, 2018 02:01 ET (06:01 GMT)
1 Year Amphion Innovations Chart |
1 Month Amphion Innovations Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions